Fundamental Analysis of ROCKET PHARMACEUTICALS INC(NASDAQ:RCKT) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to RCKT. RCKT was compared to 588 industry peers in the Biotechnology industry. While RCKT seems to be doing ok healthwise, there are quite some concerns on its profitability. RCKT has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RCKT has reported negative net income.

In the past year RCKT has reported a negative cash flow from operations.

RCKT had negative earnings in each of the past 5 years.

In the past 5 years RCKT always reported negative operating cash flow.

1.2 Ratios

RCKT has a Return On Assets (-43.37%) which is in line with its industry peers.

With a decent Return On Equity value of -49.86%, RCKT is doing good in the industry, outperforming 68.32% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-43.37%
ROE	-49.86%
ROIC	N/A

ROA(3y)-39.2%

ROA(5y)-32.4%

ROE(3y)-44.12%

ROE(5y)-37.05%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RCKT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, RCKT has more shares outstanding

The number of shares outstanding for RCKT has been increased compared to 5 years ago.

The debt/assets ratio for RCKT has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 13.08 indicates that RCKT is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 13.08, RCKT belongs to the top of the industry, outperforming 88.87% of the companies in the same industry.

RCKT has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.

With a Debt to Equity ratio value of 0.04, RCKT perfoms like the industry average, outperforming 40.75% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.04
Debt/FCF	N/A
Altman-Z	13.08

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

RCKT has a Current Ratio of 7.80. This indicates that RCKT is financially healthy and has no problem in meeting its short term obligations.

RCKT's Current ratio of 7.80 is fine compared to the rest of the industry. RCKT outperforms 71.75% of its industry peers.

RCKT has a Quick Ratio of 7.80. This indicates that RCKT is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 7.80, RCKT is in the better half of the industry, outperforming 72.09% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.8
Quick Ratio	7.8

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.64% over the past year.

EPS 1Y (TTM)10.64%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q30.43%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

RCKT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.69% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y7.95%

EPS Next 2Y16.65%

EPS Next 3Y23.46%

EPS Next 5Y33.69%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RCKT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCKT. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

RCKT's earnings are expected to grow with 23.46% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y16.65%

EPS Next 3Y23.46%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

RCKT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ROCKET PHARMACEUTICALS INC

NASDAQ:RCKT (4/26/2024, 7:12:54 PM)

After market: 21.95 -0.03 (-0.14%)

21.98

-0.12 (-0.54%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.99B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-43.37%
ROE	-49.86%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.04
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	7.8
Quick Ratio	7.8
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)10.64%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y7.95%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ROCKET PHARMACEUTICALS INC (RCKT)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens